Sweden · Delayed Price · Currency is SEK Vitrolife AB Statistics
Total Valuation
Vitrolife AB has a market cap or net worth of SEK 15.64 billion. The enterprise value is 16.50 billion.
| Market Cap | 15.64B |
| Enterprise Value | 16.50B |
Important Dates
The last earnings date was Thursday, October 22, 2026.
| Earnings Date | Oct 22, 2026 |
| Ex-Dividend Date | May 6, 2026 |
Share Statistics
Vitrolife AB has 132.73 million shares outstanding. The number of shares has decreased by -0.30% in one year.
| Current Share Class | 132.73M |
| Shares Outstanding | 132.73M |
| Shares Change (YoY) | -0.30% |
| Shares Change (QoQ) | -0.99% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 65.77% |
| Float | 71.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 21.82 |
| PS Ratio | 4.50 |
| PB Ratio | 1.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.67 |
| P/OCF Ratio | 22.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.40, with an EV/FCF ratio of 27.10.
| EV / Earnings | n/a |
| EV / Sales | 4.75 |
| EV / EBITDA | 15.40 |
| EV / EBIT | 24.46 |
| EV / FCF | 27.10 |
Financial Position
The company has a current ratio of 3.68, with a Debt / Equity ratio of 0.21.
| Current Ratio | 3.68 |
| Quick Ratio | 2.82 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 1.63 |
| Debt / FCF | 2.86 |
| Interest Coverage | 7.18 |
Financial Efficiency
Return on equity (ROE) is -46.30% and return on invested capital (ROIC) is 7.47%.
| Return on Equity (ROE) | -46.30% |
| Return on Assets (ROA) | 2.95% |
| Return on Invested Capital (ROIC) | 7.47% |
| Return on Capital Employed (ROCE) | 6.18% |
| Weighted Average Cost of Capital (WACC) | 12.50% |
| Revenue Per Employee | 3.16M |
| Profits Per Employee | -4.56M |
| Employee Count | 1,088 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 3.20 |
Taxes
In the past 12 months, Vitrolife AB has paid 144.00 million in taxes.
| Income Tax | 144.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.08% in the last 52 weeks. The beta is 1.67, so Vitrolife AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | -18.08% |
| 50-Day Moving Average | 97.71 |
| 200-Day Moving Average | 96.51 |
| Relative Strength Index (RSI) | 81.45 |
| Average Volume (20 Days) | 199,803 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vitrolife AB had revenue of SEK 3.44 billion and -4.96 billion in losses. Loss per share was -36.70.
| Revenue | 3.44B |
| Gross Profit | 2.04B |
| Operating Income | 668.00M |
| Pretax Income | -4.82B |
| Net Income | -4.96B |
| EBITDA | 1.02B |
| EBIT | 668.00M |
| Loss Per Share | -36.70 |
Balance Sheet
The company has 860.00 million in cash and 1.73 billion in debt, with a net cash position of -865.00 million or -6.52 per share.
| Cash & Cash Equivalents | 860.00M |
| Total Debt | 1.73B |
| Net Cash | -865.00M |
| Net Cash Per Share | -6.52 |
| Equity (Book Value) | 8.12B |
| Book Value Per Share | 61.16 |
| Working Capital | 1.64B |
Cash Flow
In the last 12 months, operating cash flow was 696.00 million and capital expenditures -93.00 million, giving a free cash flow of 603.00 million.
| Operating Cash Flow | 696.00M |
| Capital Expenditures | -93.00M |
| Depreciation & Amortization | 347.00M |
| Net Borrowing | -354.00M |
| Free Cash Flow | 603.00M |
| FCF Per Share | 4.54 |
Margins
Gross margin is 59.30%, with operating and profit margins of 19.42% and -144.10%.
| Gross Margin | 59.30% |
| Operating Margin | 19.42% |
| Pretax Margin | -139.97% |
| Profit Margin | -144.10% |
| EBITDA Margin | 29.51% |
| EBIT Margin | 19.42% |
| FCF Margin | 17.53% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 0.93%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 0.93% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | n/a |
| FCF Payout Ratio | 24.21% |
| Buyback Yield | 0.30% |
| Shareholder Yield | 1.25% |
| Earnings Yield | -31.15% |
| FCF Yield | 3.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Vitrolife AB is 133.00, which is 12.90% higher than the current price. The consensus rating is "Buy".
| Price Target | 133.00 |
| Price Target Difference | 12.90% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.90% |
| EPS Growth Forecast (3Y) | 29.00% |
Stock Splits
The last stock split was on May 17, 2018. It was a forward split with a ratio of 5.
| Last Split Date | May 17, 2018 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |